Saturday 17 October 2026
Export BMEA’s income statement to Excel — free account
Biomea Fusion, Inc.
BMEA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 76.5% and free cash flow grew 47.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.87
0.03
+3.57%
Follow BMEA
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 7.00 | 2.84 | 6.63 | 3.61 | 0.87 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 22.22 | 14.20 | 43.69 | 20.21 | 4.59 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 51 | 83 | 103 | 106 | 41 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | — | (1) | (5) | (42) | (82) | (117) | (138) | (62) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | (1) | (5) | (42) | (82) | (117) | (138) | (62) | |||||
| Depreciation | — | — | — | — | 0 | 1 | 1 | 2 | 2 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (0.20) | (0.51) | (1.74) | (2.80) | (3.44) | (3.83) | (1.18) | |||||
| Cash flow | — | — | — | (0.21) | (0.42) | (1.49) | (2.13) | (2.83) | (3.32) | (1.35) | |||||
| Capex | — | — | — | 0.00 | 0.00 | (0.13) | (0.04) | (0.10) | (0.01) | 0.00 | |||||
| Free cash flow | — | — | — | (0.21) | (0.43) | (1.62) | (2.17) | (2.93) | (3.33) | (1.35) | |||||
| Book value | — | — | — | 0.00 | 0.49 | 7.49 | 3.71 | 4.96 | 1.43 | 0.57 | |||||
| Shares, m | — | — | — | 6 | 11 | 24 | 29 | 34 | 36 | 52 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (1) | (4) | (35) | (62) | (97) | (120) | (70) | ||||
| Capex | — | — | — | — | 0 | (3) | (1) | (3) | 0 | — | |||||
| Free cash flow | — | — | — | (1) | (5) | (39) | (63) | (100) | (120) | (70) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 0 | 61 | 172 | 99 | 156 | 47 | 47 | ||||
| Total debt | — | — | — | — | 56 | 3 | 2 | — | — | — | |||||
| Net debt | — | — | — | 0 | (62) | (174) | (113) | (177) | (58) | (56) | |||||
| Shareholders’ equity | — | — | — | 0 | 5 | 179 | 109 | 169 | 52 | 30 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (904.15) | (16.96) | (33.49) | (51.95) | (71.23) | (98.92) | (89.23) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | (494.43) | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | 0.00 | (206.84) | (45.19) | (56.96) | (84.42) | (125.38) | (152.35) | |||||
Negative figures in brackets.
Charts ten years each
Biomea Fusion, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| VRCA Verrica Pharmaceuticals Inc. | $64.9M | — (loss-making) | — (loss-making) | −53.85% (below 0%: shrinking) | n/m | +7.63% (above 0%: growing) | 85.02% | (223.42%) | Compare |
| CING Cingulate Inc. | $63.8M | — (loss-making) | — | — | n/m | −24.28% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| FBIO Fortress Biotech, Inc. | $63.7M | 0.6× | 1.1× | +14.04% (above 0%: growing) | n/m | −115.37% (below 0%: shrinking) | 67.18% | (53.46%) | Compare |
| APLM Apollomics Inc. | $61.2M | — (loss-making) | — | — | 0.00% | +76.08% (above 0%: growing) | — | — | Compare |
| BMEA Biomea Fusion, Inc. | $60.6M | — (loss-making) | — | — | n/m | +47.80% (above 0%: growing) | 0.00% | 0.00% | |
| PLRX Pliant Therapeutics, Inc. | $60.2M | — (loss-making) | — (loss-making) | −95.03% (below 0%: shrinking) | n/m | +68.61% (above 0%: growing) | 0.00% | 0.00% | Compare |
| XLO Xilio Therapeutics, Inc. | $59.4M | — (loss-making) | — (loss-making) | +131.22% (above 0%: growing) | n/m | −26.23% (below 0%: shrinking) | 100.00% | (18.68%) | Compare |
| GANX Gain Therapeutics, Inc. | $58.1M | — (loss-making) | — (loss-making) | +27.78% (above 0%: growing) | n/m | +8.22% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CNTB Connect Biopharma Holdings Limited Sponsored ADR | $57.1M | — (loss-making) | — (loss-making) | +296.56% (above 0%: growing) | n/m | −23.48% (below 0%: shrinking) | 100.00% | (635.98%) | Compare |
| Median of peers | $60.7M | — | — | +20.91% | — | −7.92% | 67.18% | (18.68%) |
Biomea Fusion, Inc. (BMEA) key facts
- Biomea Fusion, Inc. (BMEA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, BMEA traded at $0.87, a market capitalization of $60.6 million.
- Return on equity was −152.4% and debt-to-equity 0.00.